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BACKGROUND  
This investigation is to follow up on a recent request to the Massachusetts Department of 
Public Health Bureau of Environmental Health (MDPH/BEH) from a resident for 
information on the incidence of brain cancer in a neighborhood in Medfield and the 
possibility of an association with historical exposures to tetrachloroethylene (also known 
as PCE, perchloroethylene, PERC and tetrachloroethene) in the municipal drinking water 
supply1.  PCE is a synthetic chemical that is widely used in the dry cleaning process and 
as a degreasing solvent.  PCE can travel through soils easily and as a result, contaminate 
groundwater (ATSDR 1997).   
 
The Community Assessment Program (CAP) is a division within MDPH/BEH that 
investigates reports of suspected disease clusters in communities throughout 
Massachusetts.  In response to this request, CAP staff contacted the Medfield Department 
of Public Works (DPW) and the Massachusetts Department of Environmental Protection 
(MDEP) to obtain available information about any current or historic levels of PCE in the 
municipal drinking water within the community.  In addition, CAP staff reviewed 
available cancer incidence data from the Massachusetts Cancer Registry (MCR) for the 
community of Medfield to assess whether an atypical pattern of cancer may be occurring 
there.  This report summarizes the results of MDPH/BEH’s evaluation.  
 
DISCUSSION 
Tetrachloroethylene (PCE) in Drinking Water 
The municipal drinking water for Medfield is supplied by five groundwater wells located 
within the community.  Wells 1, 2, and 6 are located within the Charles River aquifer 
while Wells 3 and 4 are located within the Neponset River aquifer (Figure 1).  The water 
system also includes five pumping facilities, two water storage tanks, and approximately 
76 miles of water main pipe (Town of Medfield 2009).   
 
MDPH obtained available analytical PCE data from the MDEP Drinking Water Program 
for the nine-year period 1988-1996.  Wells 1 and 2, which are only used during peak 
summer demand, have been treated historically for the removal of PCE.  The source of 
the PCE that was detected in these two Medfield wells is unknown.     
 
The Massachusetts Maximum Contaminant Level (MMCL) is a state-wide standard that 
applies to drinking water provided by public water systems.  Of the 15 samples collected 
from Well 1 during 1988-1996, one had levels of PCE that exceeded the MMCL of 5 
ppb.  This sample was collected in 1995 and had a PCE concentration of 9.4 ppb (Table 
1).  PCE exceedances above the MMCL in water from Well 2 occurred in 6 of 11 
samples collected during this time period.  The earliest exceedances were detected in 
1991, with a maximum concentration of 9.9 ppb detected in 1995 (Table 2) (D. 
Guterman, MDEP, personal communication, 2010; MDEP 2010).  Therefore, a 
completed exposure pathway existed in the past due to PCE in drinking water.  Overall, 
                                                 
1 This report was supported in part by funds from a cooperative agreement with the Agency for Toxic 
Substances and Disease Registry (ATSDR), U.S. Department of Health and Human Services. This 
document has not been reviewed and cleared by ATSDR.   
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the average concentration of PCE in the two wells combined during the nine-year period 
was 3.5 ppb.  
 
In 1996, an aeration tower was installed to remove PCE from the drinking water from 
Wells 1 and 2 prior to distribution.  The aeration tower was in use by December 1996 as 
indicated by samples collected both before and after treatment (MDEP 2010).  Sampling 
results from December 1996 to October 2009 indicate that no detectable levels of PCE 
were found after this treatment process was put into place.  As of November 2009, the 
aeration tower is no longer in use, and PCE is sampled on a quarterly basis per agreement 
with MDEP.  If the average concentration of PCE detected in the previous four quarters is 
greater than or equal to ½ the MMCL (2.5 ppb), then the aeration tower will be turned 
back on (K. Feeney, Medfield DPW, personal communication, 2010).  As a result, 
present and future exposures to PCE in drinking water from Wells 1 and 2 were 
eliminated as exposure pathways.   
 
In the past, it is possible that residents of Medfield could have been exposed to PCE in 
municipal water from Wells 1 and 2 via ingestion, inhalation (i.e., while showering), 
and/or dermal contact (i.e., washing hands or bathing with water containing PCE) during 
periods of peak demand (i.e., summer months).  A completed exposure pathway whereby 
PCE was detected above the MMCL is documented from about 1991 through 1996, at 
which time the aeration tower was put in use.  However, it is unlikely that a resident 
would have ingested the maximum concentration of PCE due to mixing with water from 
other wells and due to the intermittent use of the backup wells.  While houses in close 
proximity to Wells 1 and 2 are likely to receive more of their water from these two wells 
than houses farther away, mixing with water from other wells would have likely reduced 
the concentration of PCE.  This is supported by data showing samples from Wells 1 and 2 
during 1995 ranging from 3.6 to 9.9 ppb whereas levels of PCE detected in samples 
collected in November 1995 from the taps of 6 residences located throughout the 
distribution system ranged from non-detect to 1.4 ppb (D. Guterman, MDEP, personal 
communication, 2010; MDEP 2010).  
 
A secondary pathway was investigated, as PCE can also leach into drinking water from 
vinyl-lined asbestos cement water mains.  This type of lined pipe was used historically in 
the water distribution systems of several communities in Massachusetts.  It was 
confirmed, however, with the Medfield DPW that there is no vinyl lining in the drinking 
water pipes within the community of Medfield (K. Feeney, Medfield DPW, personal 
communication, 2010).  Therefore, past, present or future exposures to PCE from vinyl-
lined asbestos cement water mains were eliminated as exposure pathways.   
 
PCE Exposures and Noncancer Health Effects 
In order to evaluate the potential for noncancer health effects, exposure doses were 
estimated and compared to health guideline values for estimating noncancer health risks.  
Using highly conservative assumptions that an adult ingested 2 liters of water and a child 
ingested 1 liter of water containing the maximum concentration of PCE detected 
according to available records (i.e., 9.9 ppb in Well 2 in 1995) for 150 days per year 
(May through September) for a maximum potential exposure duration (9 years from 
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1988-1996), the estimated noncancer effects exposure dose is 0.0001 milligrams per 
kilograms per day (mg/kg/day) for adults and children.  This estimated daily exposure 
dose is substantially less than the U.S. EPA chronic oral RfD (0.01 mg/kg/day), which 
represents an estimate of a daily oral exposure that is not expected to result in adverse 
noncancer health effects (USEPA 1988).  As a result, noncancer health effects from past 
exposure to PCE in Medfield municipal water are not expected.  It is important to note 
that using the maximum concentration that was detected in Wells 1 and 2 likely 
overestimates the exposure dose since the available information indicates that the overall 
concentration of PCE reaching nearby homes would have been reduced by mixing with 
water from other wells in the distribution system.  See attachment A for more information 
on the noncancer effects exposure dose calculation.   
 
It should also be noted that sodium (a nutrient) was detected at elevated concentrations in 
Wells 1 and 2.  A maximum concentration of 40 ppm of sodium was measured in these 
wells.  This concentration exceeds the Massachusetts guideline for sodium in drinking 
water of 20 ppm.  Sodium is a naturally occurring element found in water and soil.  It is 
an essential mineral, which is necessary for the normal functioning of the body and 
maintenance of body fluids.  The Massachusetts guideline of 20 ppm in drinking water 
represents a level of sodium in water that physicians and sodium-sensitive individuals 
should be aware of in cases where sodium exposures are carefully controlled.  People 
who have difficulty regulating fluid volume as a result of several diseases such as 
hypertension and kidney failure are particularly affected by elevated levels of sodium 
(MDPH 2007).  MDPH’s fact sheet on sodium in drinking water is included in 
Attachment B.  
 
PCE Exposures and Carcinogenic Health Effects 
PCE has been classified as a probable human carcinogen by the International Agency for 
Research on Cancer (IARC) and is reasonably anticipated to be a carcinogen by the 
National Toxicology Program (NTP) of the U.S. Department of Health and Human 
Services.  These evaluations were based on limited evidence in humans and sufficient 
evidence in experimental animals.  Although brain and other nervous system cancers are 
not cancer types that are likely to be associated with exposure to PCE based on the 
epidemiological literature, exposure doses were estimated and compared to health 
guidelines for estimating cancer risk (ATSDR 1997, 2011; Cantor et al. 2006; 
Siemiatycki et al. 2006)  Extensive literature exists on the toxicity and carcinogenicity of 
PCE.  For a full discussion, refer to the ATSDR Toxicological Profile (1997) at 
http://www.atsdr.cdc.gov/ToxProfiles/tp18.pdf.   
 
 For the purposes of evaluating carcinogenic health effects, a conservative approach was 
employed.  The exposure dose received from inhalation and dermal exposures while 
showering were considered to be equal to the estimated ingestion exposure dose (USEPA 
2000).  Under the same assumptions as for the above noncancer health effects and using 
the California EPA cancer slope factor (0.54 [mg/kg/day]-1), the estimated cancer risk is 
1.6 x 10-5, indicating that past opportunities for PCE exposure via municipal drinking 
water are unlikely to result in unusual cancer risks for either adults or children.  The 
theoretical cancer risk calculation estimates an excess cancer risk in terms of the 
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proportion of the population that may be affected by a carcinogenic substance over a 
lifetime of exposure (ATSDR 2005).  In other words, the estimated cancer risk of 1.6 in 
100,000 (1.6x10-5) means that there is a probability of about one or two additional cancer 
diagnoses over background levels in a population of 100,000 people.  See Attachment A 
for more information on the calculation of the estimated cancer risk.   
 
Review of Massachusetts Cancer Registry Incidence Data 
Cancer is not just one disease, but is a term used to describe a variety of different 
diseases.  As such, studies have generally shown that different cancer types have different 
causes, patterns of incidence, risk factors, and latency periods (time between exposure to 
a cancer-causing agent and the development of the disease).  Despite numerous scientific 
and medical studies, the causes of brain and other nervous system cancers are still largely 
unknown.  Most brain and other nervous system cancers develop for no apparent reason 
and are not associated with anything that the person did or didn't do, or with any known 
exposures in the environment.  The most established risk factor for brain and other 
nervous system tumors is high-dose exposure to ionizing radiation such as that used for 
the treatment of other cancers (ACS 2009a, b).  According to the medical literature, the 
latency period for brain and other nervous system cancers could range anywhere between 
10 and 40 or 50 years.  Although exposure to PCE is not likely to be associated with the 
development of brain and other nervous system cancers, the incidence of these specific 
cancer types was evaluated by MDPH in response to a request of a concerned resident.   
 
The MCR is a division in the MDPH Bureau of Health Information, Statistics, Research, 
and Evaluation (BHISRE).  It is a population-based surveillance system that has been 
monitoring cancer incidence in the Commonwealth since 1982.  All new diagnoses of 
invasive cancer, as well as certain in situ (localized) cancers, among Massachusetts 
residents are required by law to be reported to the MCR within six months of the date of 
diagnosis (M.G.L. c.111. s 111b).  The MCR also gathers background information (e.g. 
gender, age, and address at diagnosis) on each individual reported.  This information is 
kept in a confidential database.  Data are collected daily and reviewed for accuracy and 
completeness on an annual basis.  Due to the high volume of data collected and the six-
month period between diagnosis and required reporting, the most current registry data 
that are complete will be a minimum of 2 years prior to the current date.  At the time of 
this investigation, 2002-2006 constitutes the 5-year time period for which the most recent 
and complete cancer incidence data are available.   
 
To assess the incidence of cancer in a community, the number of observed diagnoses is 
compared to the number of expected diagnoses, which is calculated based on the 
statewide cancer experience and adjusted for the population structure of the community.  
The incidence of malignant brain and other nervous system cancers in the community of 
Medfield, which had a population of about 12,300 in 2000 and encompasses 
approximately 14.5 square miles, was reviewed for the 5-year period from 2002-2006.  
During this time period, brain and other nervous system cancers occurred approximately 
as expected among males (4 observed vs. 3 expected) and as expected among females (2 
observed vs. 2 expected).  Although the number of observed diagnoses among males 
exceeded the number of expected diagnoses by one, this was likely a result of random 
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fluctuation and represents natural variation.  It should be noted that secondary brain 
tumors, which originate elsewhere in the body and then metastasize to the brain, are not 
included.    
 
Primary brain and other nervous system tumors consist of two main histology (or tissue) 
types: gliomas and meningiomas.  Gliomas are a general classification of brain and other 
nervous system tumors that includes astrocytomas, oligodendrogliomas, and 
ependymomas.  According to the American Cancer Society (ACS), gliomas account for 
approximately 80% of malignant brain and other nervous system tumors.  Astrocytomas 
are the most common type of glioma.  Glioblastoma multiforme (also referred to as 
glioblastoma for short) is a high grade, aggressive form of astrocytoma.  Glioblastomas 
account for about two-thirds of all astrocytomas and are the most common malignant 
brain tumors in adults.  Meningiomas arise from the meninges, the layers of tissue that 
surround the outer part of the brain and spinal cord.  Approximately 80% of meningiomas 
are non-malignant.  Brain and other nervous system tumors are the second most common 
cancer type among children (after leukemia) and account for over 20% of childhood 
cancers.  After a peak in childhood, the risk of brain and other nervous system cancers 
increases with age between 25 and 75 years (ACS 2009a, 2009b).   
 
The histology types and age patterns of those individuals diagnosed with malignant brain 
and other nervous system cancers in Medfield during 2002-2006 appear to be consistent 
with what would be expected based on the medical literature and national cancer 
statistics.  All six individuals, the majority of whom were adults, were diagnosed with 
gliomas.  To protect the privacy of the Medfield residents diagnosed with brain and other 
nervous system cancers, their specific cancer subtypes will not be discussed here.   
 
A review of the geographic distribution of residences of individuals diagnosed with brain 
or other nervous system cancers during this time period was based upon address at the 
time of diagnosis.  The spatial distribution was assessed by qualitatively evaluating the 
point pattern of diagnoses using a computerized geographic information system (GIS).  
The geographic distribution was generally consistent with the pattern of population 
density.  No unusual spatial pattern or concentration of diagnoses was observed.  The 
MDPH is bound by law not to make public the names or any other information (e.g., 
place of residence) that could personally identify individuals with cancer whose 
diagnoses have been reported to the MCR (M.G.L. c.111. s. 24A).  Therefore, for 
confidentiality reasons, it is not possible for the MDPH to release maps showing the 
residential locations of individuals diagnosed with cancer.   
 
CAP staff also conducted a qualitative review of more recent diagnoses of brain and other 
nervous system cancers that occurred in Medfield from 2007 to present.  As mentioned 
previously, the MCR data file for these more recent years had not yet been closed at the 
time of this investigation.  For that reason, an expected number of diagnoses for these 
years could not be calculated.  Based on the available information, although some 
diagnoses occurred among individuals whose residences at the time of diagnosis were in 
relative close proximity to one another, the geographic distribution of these more recent 
diagnoses generally followed the pattern of population density.  The histology types and 
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age patterns of those individuals also appear to be consistent with what would be 
expected.   
 
CONCLUSIONS 
1) PCE was detected at levels above the MMCL in Wells 1 and 2 from about 1991 
through 1996, at which time an aeration tower was put in place.  Based on highly 
conservative assumptions about the concentration, frequency and duration of 
potential exposures, no unusual risks of cancer or other adverse non-cancer health 
effects are expected to result from these past exposures.   
 
2) During the 5-year period from 2002-2006, the incidence of brain and other 
nervous system cancers in the community of Medfield was approximately as 
expected among males (4 observed vs. 3 expected) and as expected among 
females (2 observed vs. 2 expected) when compared to the statewide cancer 
experience.  Although the number of observed diagnoses among males exceeded 
the number of expected by one, this was likely a result of random fluctuation and 
represents natural variation.  The histology types and age patterns of those 
individuals diagnosed during this time period appear to be consistent with state 
and national trends.   
 
3) Analysis of the geographic distribution of place of residence for individuals 
diagnosed with brain and other nervous system cancers in Medfield during 2002 
to present did not reveal any unusual spatial patterns.  In general, the geographic 
distribution was consistent with the pattern of population density.     
 
Based on the MDPH’s evaluation of the available environmental data, the exposure 
pathway analysis, and risk factor information related to brain and other nervous system 
cancers, the MDPH concludes that:  
 
For adults and children in the community of Medfield, drinking, touching (i.e., 
washing hands or bathing), or breathing while showering with municipal water 
containing PCE at levels reviewed for this evaluation in the past is not expected to 
result in health effects.  Based on the available information, potential exposures 
are unlikely to be of sufficient concentration and duration to result in health 
effects.   
 
RECOMMENDATIONS 
The MDPH recommends no further investigation of the incidence of brain and other 
nervous system cancers in the community of Medfield at this time, but will continue to 
monitor the incidence of all cancer types in the community of Medfield through city/town 
cancer incidence reports published by the Massachusetts Cancer Registry.   
 
For more information about recent water quality tests conducted on drinking water in the 
community of Medfield, contact the Medfield Department of Public Works at 508-359-
8505.   
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PUBLIC HEALH ACTION PLAN 
The Public Health Action Plan contains a description of actions to be taken by the MDPH 
subsequent to completion of this Health Consultation.  The purpose of the Public Health 
Action Plan is to ensure that this health consultation not only identifies public health 
hazards, but also provides a plan of action designed to mitigate and prevent adverse 
human health effects resulting from exposure to hazardous substances in the 
environment.  Included is a commitment on the part of the MDPH to follow up on this 
plan to ensure that it is implemented.  The public health actions to be implemented by 
MDPH are as follows: 
• The MDPH will continue to monitor the incidence of all cancer types in the 
community of Medfield through city/town cancer incidence reports published by 
the Massachusetts Cancer Registry.  
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Date PCE (ppb)
3/21/1988 0.25*
8/15/1990 0.5
1/3/1991 1.0
6/17/1992 0.6
3/17/1993 0.7
4/21/1993 0.8
9/1/1993 1.1
12/16/1993 1.2
1/17/1995 9.4
4/5/1995 3.6
11/16/1995 3.6
3/26/1996 3.0
6/26/1996 4.2
9/19/1996 1.6
12/19/1996 2.0
3/21/1997 0.25*‡
* Non-detect.  Result is 1/2 of the detection limit. 
‡ Sample was collected after treatment. 
Concentrations of Tetrachloroethylene (PCE) Detected in Well 1, 1988-1997
Table 1
Medfield, Massachusetts
 
 
Date PCE (ppb)
3/21/1988 0.25*
8/15/1990 4.0
1/3/1991 5.1
6/17/1992 5.2
3/17/1993 4.3
4/21/1993 3.3
9/1/1993 8.8
12/16/1993 8.9
1/17/1995 9.9
4/5/1995 8.2
12/12/1996 0.25*‡
3/21/1997 0.25*‡
* Non-detect.  Result is 1/2 of the detection limit. 
‡ Sample was collected after treatment. 
Medfield, Massachusetts
Table 2
Concentrations of Tetrachloroethylene (PCE) Detected in Well 2, 1988-1997
Attachment A 
Exposure Dose and Cancer Risk Calculations for Exposure to PCE in Drinking Water 
Medfield, Massachusetts 
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Exposure Dose and Cancer Risk Calculation Formulas: 
 
Noncancer Health Effects Exposure Factor: 
 days 365  ED
ED  F  NC_EF ×
×=  
Noncancer Health Effects Exposure Dose (Ingestion): 
BW
NC_EF  IR  [C]
  NC_D  waterdrinking
××=  
Cancer Effects Exposure Factor: 
 days 365  years 70
ED  F  C_EF ×
×=  
Cancer Effects Exposure Dose (Ingestion): 
BW
C_EF  IR  [C]
  C_D  waterdrinking
××=  
Cancer Risk: 
CSF  C_D  CR ×=  
Where: 
  NC_EF  = Noncancer Exposure Factor (unitless) 
  F  = Frequency of Exposure (days/year) 
  ED  = Years of Exposure (years) 
  NC_D   = Noncancer Exposure Dose (mg/kg/day) 
  [C]drinking water  = Maximum Analyte Concentration in Drinking Water (mg/L) 
  IR   = Intake Rate (L/day) 
  BW  = Body Weight (kg) 
  C_EF   = Cancer Exposure Factor (unitless) 
  C_D   = Cancer Exposure Dose (mg/kg/day) 
  CR   = Cancer Risk (unitless) 
  CSF   = Cancer Slope Factor (mg/kg/day –1) 
  
Assumptions: 
1) The receptors evaluated were an adult resident and a child. 
2) The drinking water concentration was assumed to be the maximum concentration of 
PCE detected in drinking water from Well 1 or 2 from the available records.   
3) The amount of drinking water ingested was assumed to be 2 liters per day for the 
adult receptor and 1 liter per day for the child. 
4) The exposure factor was determined assuming the adult and child receptors were 
exposed to contaminated drinking water for 150 days per year (during summer 
demand only, May through September) over a 6 year time period.   
5) The average body weight was assumed to be 70 kilograms for the adult receptor and 
35 kilograms for the child receptor. 
6) For the purposes of evaluating cancer risk, exposure dose received from inhalation 
and dermal exposures while showering were considered to be equal to the estimated 
ingestion exposure dose.  
Attachment C 
 Risk Factor Information for Brain and Other Nervous System Cancers 
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1. Exposure Dose and Cancer Risk Calculations for Ingestion of Drinking Water 
Containing PCE: 
 
a. Adult 
41.0
 days 365  years 9
years 9 days/year  150 Factor Exposure EffectsHealth Noncancer =×
×=  
 
mg/kg/day 0.00012  
kg 70
0.41 L/day  2  mg/L 0.01  Dose Exposure EffectsHealth Noncancer =××=  
05.0
 days 365  years 70
years 9 days/year  150 Factor  Exposure EffectsCancer =×
×=  
mg/kg/day 0.00003  
kg 70
2 0.05 L/day  2  mg/L 0.01  Dose Exposure EffectsCancer =×××=  
0.000016  0.54  0.00003 Risk Cancer =×=  
 
b. Child 
41.0
 days 365  years 9
years 9 days/year  150 Factor  Exposure EffectsHealth Noncancer =×
×=  
 
mg/kg/day 0.00012  
kg 35
0.41 L/day  1  mg/L 0.01  Dose Exposure EffectsHealth Noncancer =××=  
05.0
 days 365  years 70
years 9 days/year  150 Factor  Exposure EffectsCancer =×
×=  
mg/kg/day 0.00003  
kg 35
2 0.05 L/day  1  mg/L 0.01  Dose Exposure EffectsCancer =×××=  
0.000016 0.54  0.00003 Risk Cancer =×=  
NOTES: 
1.  The EPA Chronic Oral RfD for PCE is 0.01 mg/kg/day.     
2.  The California EPA has calculated an oral cancer slope factor of 0.54 (mg/kg/d)-1.  
Attachment B 
MDPH Sodium Fact Sheet 
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 Risk Factor Information for Brain and Other Nervous System Cancers 
 
Source: Community Assessment Program, Bureau of Environmental Health, Massachusetts Department of Public Health 
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How to Use this Factsheet 
 
This risk factor summary was developed to serve as a general fact sheet.  It is an 
overview and should not be considered exhaustive.  For more information on other 
possible risk factors and health effects being researched, please see the References 
section. 
 
A risk factor is anything that increases a person’s chance of developing cancer.  Some 
risk factors can be controlled while others cannot.  Risk factors can include hereditary 
conditions, medical conditions or treatments, infections, lifestyle factors, or 
environmental factors.  Although risk factors can influence the development of cancer, 
most do not directly cause cancer.  An individual’s risk for developing cancer may 
change over time due to many factors and it is likely that multiple risk factors influence 
the development of most cancers.  Knowing the risk factors that apply to specific 
concerns and discussing them with your health care provider can help to make more 
informed lifestyle and health-care decisions.   
 
For cancer types with environmentally-related risk factors, an important factor in 
evaluating cancer risk is the route of exposure.  This is particularly relevant when 
considering exposures to chemicals in the environment.  For example, a particular 
chemical may have the potential to cause cancer if an individual breathes the chemical in.  
That same chemical may not increase the risk of cancer similarly if an individual comes 
into contact with the chemical by touching it.  In addition, an individual must generally 
be exposed to a chemical at a sufficient dose and for a sufficient duration of time for an 
adverse health effect to occur.   
 
Gene-environment interactions are another important area of cancer research.  An 
individual’s risk of developing cancer may depend on a complex interaction between 
their genetic make-up and exposure to an environmental agent (for example, a virus or a 
chemical contaminant).  This may explain why some individuals have a fairly low risk of 
developing cancer as a result of an environmental factor or exposure, while others may be 
more vulnerable.  
 
Key Statistics 
 
The American Cancer Society estimates 22,020 individuals will be diagnosed with 
malignant (cancerous) tumors of the brain or other nervous system (ONS) in the U.S. in 
2010: 11,980 men and 10,040 women.  These numbers would likely be much higher if 
non-malignant (non-cancerous) tumors were also included.  In Massachusetts, incidence 
rates of brain and ONS cancers have generally remained steady from 2003 to 2007 
among adults and children combined.  Nationally, brain and ONS cancers are considered 
to be the second most common cancers in children.  After a peak in childhood (generally 
under 10 years of age), the risk of brain and ONS cancers increases with age between 25 
and 75 years.   
 
Types of Brain and Other Nervous System Cancers 
Attachment C 
 Risk Factor Information for Brain and Other Nervous System Cancers 
 
Source: Community Assessment Program, Bureau of Environmental Health, Massachusetts Department of Public Health 
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The term "cancer" is used to describe a variety of diseases associated with abnormal cell 
and tissue growth.  Cancers are classified by the location in the body where the disease 
originated (the primary site) and the tissue or cell type of the cancer (histology). 
 
Brain and ONS tumors can be either malignant or non-malignant, and in either case can 
be life threatening, although malignant tumors generally present greater concerns.  In 
addition, the brain is a site where both primary and secondary malignant tumors can 
arise; secondary brain tumors generally originate elsewhere in the body and then 
metastasize, or spread, to the brain.  Primary brain and ONS tumors consist of two main 
types: gliomas and meningiomas.  Gliomas are a general classification of tumors that 
include a variety of types, named for the cells from which they arise: astrocytomas, 
oligodendrogliomas, and ependymomas.  When considering only malignant brain and 
ONS tumors, approximately 80% are gliomas.  Meningiomas, the most common ONS 
tumor in adults, arise from the meninges, which are tissues that surround the outer part of 
the spinal cord and brain.  They account for about 33% of all (malignant and non-
malignant) primary brain and ONS tumors reported in adults.  Men are generally more 
likely to develop gliomas than women, while women are more likely to develop 
meningiomas.  Furthermore, the incidence of gliomas is highest among white individuals, 
whereas the incidence of meningiomas is highest among African Americans.  In addition 
to these main subtypes, there are a number of rare brain and ONS tumors.   
 
Established Risk Factors 
 
Most brain and ONS cancers develop for no apparent reason and are not associated with 
specific risk factors.   
 
Hereditary Conditions 
 
Rare cases of brain and ONS cancer run in some families.  Brain tumors in some persons 
are associated with hereditary syndromes such as neurofibromatosis types I and II, Li-
Fraumeni syndrome, and tuberous sclerosis.  Neurofibromatosis type I (von 
Recklinghausen disease) is the most common inherited cause of brain or spinal cord 
tumors.  Von Hippell-Lindau disease is associated with an inherited tendency to develop 
blood vessel tumors of the cerebellum.  Overall, inherited syndromes that predispose 
individuals to brain tumors appear to be present in fewer than 5% of brain tumor patients.  
 
Environmental Exposures 
 
The most established risk factor for brain and ONS tumors (either non-malignant or 
malignant) is high-dose exposure to ionizing radiation (i.e., x-rays and gamma rays).  
Most radiation-induced brain and ONS tumors are caused by radiation to the head from 
the treatment of other cancers.  These brain tumors usually develop around 10 to 15 years 
after the radiation.  Meningiomas are the most common type of tumors that result from 
high-dose exposure to ionizing radiation, but tumors of other types have also occurred, 
including gliomas.   
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Possible Risk Factors 
 
 Medical Conditions 
 
Head injury has long been suspected to be a possible risk factor for later development of 
brain and ONS tumors and continues to be studied by scientists.  Of those studies that 
have found a positive association, head trauma was most strongly linked to the 
development of meningiomas compared to other types of brain and ONS tumors.  
Overall, additional research is necessary before a definitive link can be established.   
 
 Lifestyle Factors 
 
The association between the development of brain and ONS cancers and N-nitroso 
compounds has been heavily researched.  These compounds and their precursors, such as 
nitrite, are ubiquitous in our environment and have been found in tobacco smoke, 
cosmetics, automobile interiors, and cured meats.  Several studies have concluded that an 
increased risk of pediatric brain tumors is associated with high levels of nitrite intake 
from maternal cured meat consumption during pregnancy.  However, these studies have 
been criticized as many years have often passed between the mother’s pregnancy and her 
interview, making recall less accurate.   
 
 Environmental Exposures 
 
The National Cancer Institute reports that occupational exposure to radiation or certain 
chemicals has been associated with increased risk of brain cancer.  As a result, workers in 
the nuclear industry, pathologists and embalmers who work with formaldehyde, workers 
who make plastics using vinyl chloride, and workers who make textile and plastics with 
acrylonitrile may have an increased risk of brain cancer.  Exposures from working in 
synthetic rubber manufacturing or petroleum refining/production are also being 
investigated.   
 
Other Risk Factors That Have Been Investigated 
 
With cellular phones becoming increasingly common, there is growing concern over a 
link between their use and brain and ONS tumors.  Cell phones emit radiofrequency 
radiation, a form of energy on the electromagnetic spectrum between FM radio waves 
and those used in microwave ovens.  They do not emit ionizing radiation, which has been 
shown to damage DNA and has the ability to cause cancer.  Several recent studies have 
found no excess risk between cell phone use and brain and ONS tumors.  However, no 
studies have investigated the latent effects of long-term heavy use of cell phones due to 
their relatively recent widespread usage.   
 
Many studies have been conducted to investigate links between brain and ONS cancers 
and environmental factors, including: residential power line exposure; viruses and 
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infections; aspartame (a sugar substitute), and pesticides.  To date, however, there is no 
strong evidence to link these factors to brain tumors.   
 
Brain and Other Nervous System Cancers in Children 
 
Brain and ONS tumors are the second most common cancers in children and account for 
over 20% of malignant tumors diagnosed among children less than 20 years of age.  
Approximately 4,030 brain and ONS tumors are diagnosed each year in children under 
the age of 20, with about 25% of these considered non-malignant tumors.  About half of 
all childhood brain tumors are astrocytomas and 20% are primitive neuroectodermal 
tumors (PNET).  Medulloblastomas are PNETs that develop in the cerebellum whereas 
pineoblastomas are PNETs that develop in the pineal gland.  The incidence rate of brain 
and ONS cancers in children has not changed significantly in recent years.  In general, 
boys are at a slightly higher risk than girls for developing brain and ONS cancers.  The 
vast majority of brain and ONS cancers in children occurs for no apparent reason and is 
not associated with any specific risk factors.   
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